DVN

Devon Energy

$41.54

-1.21%
Nov 20, 2026
Bobby Quantitative Model
Devon Energy Corporation is an independent upstream oil and gas producer focused on U.S. shale, with roughly two-thirds of production from the Permian Basin and additional positions in the Anadarko and Bakken plays; following the Coterra merger it gains a foothold in the gas-driven Appalachian Basin, and at year-end 2025 it reported 2.4 billion barrels of proved reserves and net production of about 840,000 barrels of oil equivalent per day at a 73% oil/NGL and 27% gas mix. Devon is a large-cap, pure-play shale operator rather than an integrated major, distinguished by its multi-basin scale, oil-weighted production and a shareholder-return model built on a fixed-plus-variable dividend and buybacks. The current investor debate centers on the Coterra combination — visible in the jump in shares outstanding from roughly 621 million to 1.14 billion and revenue growth of 58.4% year over year in Q3 2026 — and whether the enlarged, more gas-exposed asset base can sustain per-share cash returns. Sentiment has been complicated by BP's decision to walk away from a potential $4.5 billion Eagle Ford shale deal, which weakens Devon's asset-sale optionality and its negotiating position with activist investors, while a sharp November pullback in the shares has refocused attention on oil-price sensitivity and capital discipline.

People also watch

ConocoPhillips

ConocoPhillips

COP

Analysis
EOG Resources

EOG Resources

EOG

Analysis
Occidental Petroleum

Occidental Petroleum

OXY

Analysis
Diamondback Energy

Diamondback Energy

FANG

Analysis
EQT

EQT

EQT

Analysis

BobbyInvestment Opinion: Should I buy DVN Today?

Rating: Hold with a constructive bias. The core thesis is that Devon's 8.70x trailing and 8.33x forward earnings, 4.02x EV/EBITDA and 3.43x price-to-free-cash-flow already discount much of the post-Coterra integration risk, while the $59.81 average target implies 42.5% upside — but the 17.60% one-month decline, the -12.87 point relative-strength gap versus SPY and Bernstein's November 12 downgrade to Market Perform argue against chasing the 'strong_buy' consensus before the next quarter confirms margin stabilization. In short, the stock looks cheap on cash flow but the evidence of per-share value creation from the 84% share-count increase is not yet in hand.

The supporting evidence is genuinely two-sided. On valuation, the 8.70x PE sits in the lower-middle of a historical 4.7x-66.2x band and well below the 13.1x recorded at the end of Q3 2026, price-to-book of 1.48x is a steep discount to the 2.4-3.6x of 2022-2023, and the 8.2% FCF yield on $1.878 billion of trailing free cash flow is near multi-year lows for the multiple. Cash returns are covered: Q3 2026 operating cash flow of $2.808 billion funded $1.784 billion of capex, $366 million of dividends and $414 million of buybacks, with a 23.4% payout ratio and 2.69% yield. But profitability is volatile — net margin fell from 25.77% in Q2 to 14.69% in Q3 and gross margin from 55.95% to 48.89% — revenue fell 7.5% sequentially to $6.86 billion, and Q2 free cash flow was -$373 million on $4.047 billion of capex. Against the Oil & Gas E&P industry, the 8.70x PE and 4.02x EV/EBITDA are in line to modestly cheap, so the discount is real but not extreme.

The biggest risks that could invalidate the thesis are (1) a sustained oil-price rollover hitting a 73% oil/NGL mix, (2) Coterra synergies failing to offset the dilution from 621 million to 1.142 billion shares, and (3) the loss of asset-sale optionality after BP walked away from the $4.5 billion Eagle Ford deal. This Hold would upgrade to Buy if the stock holds the November low near $42.21 and Q4 shows gross margin recovering above 50% with positive free cash flow, or if the price falls toward the $34.23 52-week low while the $59.81 consensus target holds. It would downgrade to Sell if gross margin breaks below the Q1 2026 trough of 12.14%, if free cash flow turns negative for a second consecutive quarter, or if additional analysts follow Bernstein to Market Perform. Net verdict: fairly valued to modestly undervalued relative to its own history and peers, but not yet a compelling buy until per-share cash returns post-merger are demonstrated.

Sign up to view all

DVN 12-Month Price Forecast

The forward view is genuinely balanced: Devon trades at 8.70x trailing and 8.33x forward earnings with an 8.2% free-cash-flow yield, which is cheap relative to its own history and in line to modestly cheap versus large-cap shale peers, and the $59.81 average target implies 42.5% upside. But the near-term evidence is deteriorating — a 17.60% one-month decline against a 4.73% SPY drop, gross margin down 7.06 points sequentially, revenue down 7.5% quarter over quarter, and Bernstein's November 12 downgrade — so the 'strong_buy' consensus looks like it is lagging the fundamental reality. The pivotal variable is whether the enlarged 1.142 billion share base can generate per-share cash returns that justify the Coterra deal; if Q4 shows margin stabilization and positive free cash flow, the multiple looks deeply discounted and the stance would upgrade to bullish. Conversely, a break below the November low of $42.21 or a second consecutive negative free-cash-flow quarter would push the stance to bearish with the $34.23 52-week low as the anchor. With a 61% spread between the $44 low and $71 high target, the market is pricing uncertainty rather than conviction, which argues for patience over aggression.

Historical Price
Current Price $41.54
Average Target $51.91
High Target $71.00
Low Target $34.23

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Devon Energy's 12-month outlook, with a consensus price target around $59.81 and implied upside of +44.0% versus the current price.

Average Target

$59.81

28 analysts

Implied Upside

+44.0%

vs. current price

Analyst Count

28

covering this stock

Price Range

$44 - $71

Analyst target range

Buy
26 (93%)
Hold
2 (7%)
Sell
0 (0%)

Coverage is deep and overwhelmingly bullish: 27 analysts cover Devon with 26 Buy ratings, 2 Hold and 0 Sell, producing a consensus recommendation of "strong_buy" and a recommendation mean of 1.32 (where 1.0 is a strong buy). The average target price of $59.81 implies roughly 42.5% upside from the current $41.96, a gap that is unusually wide for a large-cap and suggests the sell-side has not yet marked estimates to the recent price collapse. Consensus 2027 EPS of $5.43 (range $4.48-$6.21) and revenue of $25.40 billion (range $22.00-$28.21 billion) underpin that optimism, and the bullish tilt is corroborated by recent actions — UBS, Truist, Morgan Stanley, JP Morgan and Barclays all reiterated Buy/Overweight ratings in early-to-mid November. The target range of $44.00 to $71.00 is extremely wide — a 61% spread from low to high — signaling genuine disagreement about the post-Coterra earnings power. The $71 high target implies multiple expansion toward 13x forward earnings and assumes oil prices stay elevated, integration synergies materialize and the Appalachian gas exposure becomes a growth driver rather than a drag; the $44 low target, just 4.9% above the current price, effectively prices in margin compression, continued commodity weakness and skepticism about per-share accretion after the 84% increase in share count. The most notable signal is Bernstein's downgrade to Market Perform from Outperform on November 12, the sole recent negative action and one that aligns with the stock's 17.6% one-month decline — a warning that the consensus "strong buy" may be lagging the fundamental reality, and that the wide target spread reflects high uncertainty rather than high conviction.

Drowning in data?

Find the real signal!

Bulls vs Bears: DVN Investment Factors

The bear case currently has stronger near-term evidence: the stock is down 17.60% in a month against a 4.73% SPY decline, margins compressed sharply from Q2 to Q3, revenue missed and fell sequentially, and the sole recent analyst action was Bernstein's November 12 downgrade to Market Perform. The bull case rests on valuation and consensus rather than momentum — an 8.70x PE near the low end of its historical range, a 3.43x price-to-free-cash-flow, an 8.2% FCF yield, and a 42.5% gap to the $59.81 average target that suggests the sell-side has not marked estimates to the price collapse. The single most important tension is whether the enlarged, 84%-diluted post-Coterra share base can generate per-share cash returns that justify the deal — if integration synergies and oil prices hold, the multiple looks deeply discounted; if not, the $44 low target is the realistic anchor. The unusually wide $44-$71 target spread (61%) signals genuine disagreement about post-merger earnings power rather than high conviction, so the 'strong_buy' consensus should be treated with caution until the next quarter confirms margin stabilization.

Bullish

  • Sell-side consensus overwhelmingly bullish: 26 of 27 covering analysts rate Devon Buy with zero Sells, producing a 'strong_buy' consensus and a 1.32 recommendation mean. The $59.81 average target implies 42.5% upside from $41.96, and UBS, Truist, Morgan Stanley, JP Morgan and Barclays all reiterated Buy/Overweight in early-to-mid November even as the stock fell.
  • Valuation compressed to multi-year lows: The 8.70x trailing PE sits in the lower-middle of a historical band that has ranged from 4.7x to 66.2x, and is well below the 13.1x recorded at the end of Q3 2026. Price-to-book of 1.48x is a steep discount to the 2.4-3.6x multiples the stock commanded in 2022-2023, while price-to-free-cash-flow of 3.43x is near multi-year lows.
  • Cash generation comfortably funds returns: Q3 2026 operating cash flow of $2.808 billion covered $1.784 billion of capex, $366 million of dividends and $414 million of buybacks with room to spare. The 23.4% payout ratio and 2.69% dividend yield look sustainable, and trailing free cash flow of $1.878 billion equates to an 8.2% FCF yield on the $23.0 billion market cap.
  • Coterra deal transforms scale and mix: Revenue grew 58.39% year over year to $6.86 billion in Q3 2026, and proved reserves rose to 2.4 billion barrels of oil equivalent from 2.2 billion. The combination adds Appalachian gas exposure and lifts production to roughly 840,000 barrels of oil equivalent per day, creating a multi-basin operator with greater diversification than a Permian-only pure play.

Bearish

  • Momentum collapse is idiosyncratic: The stock is down 17.60% over the past month versus a 4.73% decline for SPY, a -12.87 percentage point relative-strength gap, and down 14.89% over three months. With a beta of only 0.477, this weakness cannot be explained by market beta, and the latest session's -3.45% drop to $41.96 on 14.7 million shares shows selling pressure is still active.
  • Margins deteriorating sequentially: Gross margin fell from 55.95% in Q2 2026 to 48.89% in Q3, and operating margin compressed from 34.50% to 21.72%. Net income dropped from $1.911 billion to $1.008 billion quarter over quarter, and the Q1 2026 trough of $120 million net income on a 3.15% net margin shows how violently earnings swing with realizations.
  • Dilution threatens per-share returns: Shares outstanding jumped from roughly 621 million to 1.142 billion, an 84% increase, and the $44 low analyst target sits just 4.9% above the current price, effectively pricing in skepticism about per-share accretion. The 1.34x PS ratio versus a historical band of roughly 4.6x-10.2x reflects both the larger revenue base and a de-rating in sentiment.
  • Failed Eagle Ford sale weakens optionality: BP walked away from a potential $4.5 billion Eagle Ford shale deal, which removes a deleveraging and capital-recycling lever and weakens Devon's negotiating position with activist investors. It also highlights the difficulty of U.S. shale asset sales, limiting management's ability to reshape the portfolio post-merger.

DVN Technical Analysis

Devon is in a recovery trend that has stalled badly: the stock is up 16.98% over the past year versus a 10.62% gain for SPY, yet at $41.96 it sits at just 42.4% of its 52-week range of $34.23 to $52.71, having given back most of the ground gained during the summer and autumn rally. That positioning — closer to the low than the high despite a positive 1-year return — points to a market that has lost conviction rather than a clean momentum story, and the 22.7% max drawdown confirms the stock has already suffered a meaningful correction within the period. Momentum has deteriorated sharply: the stock is down 17.60% over the past month and 14.89% over three months, a stark reversal from the 16.98% 1-year gain, and the 1-month relative strength of -12.87 percentage points versus SPY shows this is idiosyncratic weakness, not just sector beta. The 3-month relative strength of -10.64 and 6-month relative strength of -9.07 confirm the underperformance is persistent rather than a one-off, and the most recent session's -3.45% drop to $41.96 on 14.7 million shares suggests selling pressure is still active rather than exhausted. The key levels are clear: resistance sits at the $52.71 52-week high, roughly 25.6% above the current price, while support is the $34.23 52-week low, about 18.4% below; a break below the November low near $42.21 would open the path toward the mid-$30s, whereas reclaiming $46-47 would signal the pullback is being bought. Notably, the beta of 0.477 implies the stock has historically moved less than half as much as the market, which is unusual for an E&P name and suggests the recent 17.6% one-month decline is company- or commodity-specific rather than broad-market driven — a distinction that matters for position sizing, since low beta offers little comfort when the drawdown is idiosyncratic.

Beta

0.48

0.48x market volatility

Max Drawdown

-22.7%

Largest decline past year

52-Week Range

$34-$53

Price range past year

Annual Return

+18.1%

Cumulative gain past year

PeriodDVN ReturnS&P 500
1m-16.7%-9.7%
3m-15.4%-9.9%
6m-12.0%-7.5%
1y+18.1%+4.7%
ytd+9.7%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

DVN Fundamental Analysis

Revenue has inflected dramatically, but largely through acquisition rather than organic growth: Q3 2026 revenue of $6.86 billion grew 58.39% year over year from $4.331 billion, and the quarterly sequence of $3.807 billion (Q1), $7.417 billion (Q2) and $6.86 billion (Q3) reflects the Coterra combination closing mid-year, with shares outstanding jumping from 621 million to 1.142 billion. The sequential decline from Q2's $7.417 billion to Q3's $6.86 billion (-7.5%) is a warning that the enlarged base is already seeing top-line erosion, consistent with the Zacks note that Q3 delivered an EPS beat but a revenue miss amid production challenges. The single reported segment line of $5.939 billion in NGL product sales underscores how commodity-price and mix-driven the revenue base is, meaning growth durability depends on oil and gas prices rather than volume expansion alone. Profitability is strong but volatile: Q3 2026 net income was $1.008 billion on a 14.69% net margin, down sharply from Q2's $1.911 billion and 25.77% margin, while gross margin fell from 55.95% in Q2 to 48.89% in Q3 and operating margin compressed from 34.50% to 21.72%. The Q1 2026 trough — $120 million of net income, a 3.15% net margin and a 12.14% gross margin — shows how violently earnings swing with realizations, and the trailing figures (15.37% net margin, 25.55% gross margin, 22.43% operating margin) sit below the 2022-2023 up-cycle levels of roughly 26-40% gross margins. The balance sheet is a relative strength: debt-to-equity of 0.566 and a current ratio of 0.980 are manageable for the sector, ROE of 17.01% and ROA of 6.51% are respectable, and Q3 operating cash flow of $2.808 billion comfortably funded $1.784 billion of capex, $366 million of dividends and $414 million of buybacks. However, trailing free cash flow of $1.878 billion against a $23.0 billion market cap is only a 8.2% FCF yield, and Q2's negative free cash flow of -$373 million on $4.047 billion of capex shows the acquisition-integration period strained cash generation; the payout ratio of 23.4% and 2.69% dividend yield look sustainable, but the low current ratio and $750 million of Q3 debt repayment mean liquidity deserves monitoring.

Quarterly Revenue

$6.9B

2026-09

Revenue YoY Growth

+58.4%

YoY Comparison

Gross Margin

48.9%

Latest Quarter

Free Cash Flow

$1.9B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

N G L Product Sales

Open an Account, get $2 TSLA now!

Valuation Analysis: Is DVN Overvalued?

Because Devon is solidly profitable — trailing EPS of $0.1149 is positive and Q3 net income was $1.008 billion — the PE ratio is the appropriate primary metric, and the trailing PE of 8.70x against a forward PE of 8.33x implies the market expects only modest earnings growth, a mere 4.4% compression in the multiple. That narrow gap is telling: with consensus 2027 EPS estimated at $5.43 versus the trailing $0.11, the forward multiple appears to be built on a dramatically higher earnings base, suggesting the market is skeptical that current commodity-driven profitability persists. On the secondary metrics, the PS ratio of 1.34x, EV/Sales of 2.73x and EV/EBITDA of 4.02x all sit at levels typical of a mature, cyclical E&P rather than a growth story. Against the Oil & Gas Exploration & Production industry, Devon's 8.70x trailing PE and 4.02x EV/EBITDA are broadly in line to modestly cheap for large-cap shale producers, and its 1.48x price-to-book is a discount to the 2.4-3.6x book multiples the stock commanded in 2022-2023. The premium case rests on the 17.01% ROE and 22.43% operating margin, which are competitive, but the 1.34x PS ratio versus a historical band of roughly 4.6x-10.2x over the past several years shows how far the multiple has compressed — a function of both the larger post-merger revenue base and a de-rating in sentiment. Historically, Devon's PE has ranged from about 4.7x in mid-2022 to 66.2x in Q1 2026, with the current 8.70x sitting in the lower-middle of that band and well below the 13.1x recorded at the end of Q3 2026; the price-to-free-cash-flow ratio of 3.43x and price-to-operating-cash-flow of 3.43x are near multi-year lows. This places the stock closer to the value end of its own historical range, which could signal opportunity if oil prices hold — the Motley Fool piece arguing oil stays elevated until 2027 supports that case — but could equally reflect the market pricing in integration risk, the failed Eagle Ford sale and the dilution from 621 million to 1.14 billion shares.

PE

8.7x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 5x~13x

vs. Industry Avg

12.8x

Industry PE ~12.8x*

EV/EBITDA

4.0x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on earnings volatility and integration strain. Net income swung from $120 million in Q1 2026 (3.15% net margin) to $1.911 billion in Q2 (25.77%) and back to $1.008 billion in Q3 (14.69%), while gross margin fell from 55.95% to 48.89% sequentially — a reminder that results are driven by commodity realizations rather than volume. The 84% increase in shares outstanding to 1.142 billion dilutes per-share metrics, Q2 free cash flow was negative at -$373 million on $4.047 billion of capex, and a current ratio of 0.980 with debt-to-equity of 0.566 leaves limited liquidity headroom after $750 million of Q3 debt repayment. Revenue concentration in NGL product sales of $5.939 billion and a 73% oil/NGL mix mean a sustained oil-price decline flows almost directly to the bottom line.

Market and competitive risks are dominated by valuation compression and sentiment deterioration. The stock trades at 8.70x trailing and 8.33x forward earnings, and the narrow 4.4% gap implies the market expects only modest earnings growth despite consensus 2027 EPS of $5.43 versus trailing $0.11 — a disconnect that could resolve either way. The 17.60% one-month decline with a -12.87 point relative-strength gap versus SPY, against a beta of only 0.477, confirms the weakness is company- and commodity-specific rather than market-driven, so low beta offers no protection. BP's abandonment of the $4.5 billion Eagle Ford deal removes asset-sale optionality and weakens management's hand with activists, while the Appalachian gas exposure added via Coterra introduces sensitivity to weak natural gas prices, as evidenced by peer CNX's Q3 miss on lower gas prices and output decline.

Worst-case scenario: oil prices roll over, Coterra synergies disappoint, and the market re-rates the stock toward the $44 low analyst target or below. A break of the November low near $42.21 would open the path toward the $34.23 52-week low, which is 18.4% below the current $41.96 — and the 22.7% max drawdown already recorded shows that magnitude of loss is realistic within a single cycle. In a harsher scenario where the multiple compresses toward the 4.7x PE trough seen in mid-2022, downside could extend beyond the 52-week low, implying losses of roughly 18% to 25% from current levels before any recovery.

FAQ

Ranked by severity: first, commodity-price risk — with a 73% oil/NGL mix, a sustained oil decline below $65/bbl flows almost directly to earnings, as shown by net income swinging from $120 million in Q1 2026 (3.15% margin) to $1.911 billion in Q2 and back to $1.008 billion in Q3. Second, integration and dilution risk — shares outstanding jumped 84% to 1.142 billion, Q2 free cash flow was -$373 million on $4.047 billion of capex, and the $44 low target prices in skepticism about per-share accretion. Third, sentiment and momentum risk — the stock is down 17.60% in a month with a -12.87 point relative-strength gap versus SPY, and Bernstein downgraded to Market Perform on November 12; with a beta of only 0.477, low market correlation offers no protection against idiosyncratic weakness. Fourth, asset-optionality and liquidity risk — BP walked away from the $4.5 billion Eagle Ford deal, removing a deleveraging lever, while a current ratio of 0.980 and debt-to-equity of 0.566 leave limited headroom after $750 million of Q3 debt repayment.

The scenario framework assigns 50% to the base case, 25% to the bull case and 25% to the bear case. The base case targets $44.00-$59.81, assuming oil trades in a moderate range, Coterra integration proceeds without surprises, margins stabilize near Q3 levels and the stock grinds toward the $59.81 average target as the 'strong_buy' consensus holds. The bull case targets $59.81-$71.00 and requires oil above $80/bbl into 2027, quantified Coterra synergies, gross margin recovering above 50% with positive free cash flow, and multiple expansion from 8.33x toward 11x-13x on 2027 EPS of $5.43. The bear case targets $34.23-$44.00 on an oil rollover, disappointing synergies and a break of the $42.21 November low. The base case is most likely, and its key assumption is that free cash flow turns sustainably positive after Q2's -$373 million while the 23.4% payout ratio is maintained.

On the primary metric, DVN looks modestly undervalued relative to its own history. The 8.70x trailing PE sits in the lower-middle of a historical band of roughly 4.7x to 66.2x and well below the 13.1x recorded at the end of Q3 2026, while the 8.33x forward PE implies the market expects only a 4.4% compression in the multiple despite consensus 2027 EPS of $5.43 versus trailing EPS of $0.11. Secondary metrics reinforce the discount: price-to-book of 1.48x versus 2.4-3.6x in 2022-2023, price-to-free-cash-flow of 3.43x near multi-year lows, and a 1.34x PS ratio versus a historical band of roughly 4.6x-10.2x. Against the Oil & Gas E&P industry, the 8.70x PE and 4.02x EV/EBITDA are in line to modestly cheap, so the discount is real but not extreme. What the valuation implies is skepticism — the market is pricing integration risk, the failed $4.5 billion Eagle Ford sale and dilution, not expecting a re-rating until per-share cash returns are demonstrated.

The risk/reward is asymmetric but conditional. Upside to the $59.81 average target is 42.5% and the high target of $71 implies roughly 69% upside, while the $44 low target sits just 4.9% above the current $41.96 and the $34.23 52-week low implies about 18.4% downside — a favorable ratio on paper. The catch is that the near-term evidence is deteriorating: the stock is down 17.60% in a month versus -4.73% for SPY, gross margin fell from 55.95% to 48.89% sequentially, and Q2 free cash flow was -$373 million. At 8.33x forward earnings and a 3.43x price-to-free-cash-flow, much of the bad news looks priced in, but the 84% share-count increase means per-share value creation from Coterra is unproven. It is a reasonable buy for value-oriented investors who can tolerate commodity volatility and wait for Q4 confirmation of margin stabilization and positive free cash flow; it is not a buy for momentum or short-term traders.

DVN is better suited to a medium-to-long-term holding than to short-term trading. It is a mature, cyclical E&P with volatile earnings — quarterly net income ranged from $120 million to $1.911 billion over the past four quarters — and a beta of 0.477 that historically dampens market correlation but did not prevent a 17.60% one-month decline, so short-term price action is driven by oil headlines and sentiment rather than fundamentals. The 2.69% dividend yield with a 23.4% payout ratio and $414 million of Q3 buybacks provide a modest cash-return floor that rewards patience, and the 42.5% gap to the $59.81 consensus target is unlikely to close until two to three quarters of post-merger per-share cash returns are demonstrated. A concrete minimum holding period of 12-24 months is appropriate, long enough to see Q4 2026 and at least two subsequent quarters confirm margin stabilization and positive free cash flow, and to allow the Coterra integration thesis to play out.